首页> 美国卫生研究院文献>Antimicrobial Agents and Chemotherapy >Antistaphylococcal Effect Related to the Area under the Curve/MIC Ratio in an In Vitro Dynamic Model: Predicted Breakpoints versus Clinically Achievable Values for Seven Fluoroquinolones
【2h】

Antistaphylococcal Effect Related to the Area under the Curve/MIC Ratio in an In Vitro Dynamic Model: Predicted Breakpoints versus Clinically Achievable Values for Seven Fluoroquinolones

机译:在体外动力学模型中与曲线/ MIC比值下的面积相关的抗葡萄球菌作用:预测的断点对七个氟喹诺酮类药物的临床可实现值

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Prediction of the relative efficacies of different fluoroquinolones is often based on the ratios of the clinically achievable area under the concentration-time curve (AUC) to the MIC, usually with incorporation of the MIC50 or the MIC90 and with the assumption of antibiotic-independent patterns of the AUC/MIC-response relationships. To ascertain whether this assumption is correct, the pharmacodynamics of seven pharmacokinetically different quinolones against two clinical isolates of Staphylococcus aureus were studied by using an in vitro model. Two differentially susceptible clinical isolates of S. aureus were exposed to two 12-h doses of ciprofloxacin (CIP) and one dose of gatifloxacin (GAT), gemifloxacin (GEM), grepafloxacin (GRX), levofloxacin (LVX), moxifloxacin (MXF), and trovafloxacin (TVA) over similar AUC/MIC ranges from 58 to 932 h. A specific bacterial strain-independent AUC/MIC relationship with the antimicrobial effect (IE) was associated with each quinolone. Based on the IE-log AUC/MIC relationships, breakpoints (BPs) that are equivalent to a CIP AUC/MIC ratio of 125 h were predicted for GRX, MXF, and TVA (75 to 78 h), GAT and GEM (95 to 103 h) and LVX (115 h). With GRX and LVX, the predicted BPs were close to those established in clinical settings (no clinical data on other quinolones are available in the literature). To determine if the predicted AUC/MIC BPs are achievable at clinical doses, i.e., at the therapeutic AUCs (AUCthers), the AUCther/MIC50 ratios were studied. These ratios exceeded the BPs for GAT, GEM, GRX, MXF, TVA, and LVX (750 mg) but not for CIP and LVX (500 mg). AUC/MIC ratios above the BPs can be considered of therapeutic potential for the quinolones. The highest ratios of AUCther/MIC50 to BP were achieved with TVA, MXF, and GEM (2.5 to 3.0); intermediate ratios (1.5 to 1.6) were achieved with GAT and GRX; and minimal ratios (0.3 to 1.2) were achieved with CIP and LVX.
机译:通常基于浓度-时间曲线(AUC)与MIC的临床可达到面积之比来预测不同氟喹诺酮类药物的相对疗效,通常是结合MIC50或MIC90并假定与抗生素无关AUC / MIC响应关系。为了确定该假设是否正确,使用体外模型研究了七个药代动力学不同的喹诺酮类药物对两种金黄色葡萄球菌临床分离株的药效学。将两个易感性金黄色葡萄球菌临床分离株暴露于两个12小时剂量的环丙沙星(CIP)和一剂加替沙星(GAT),吉非沙星(GEM),格列沙星(GRX),左氧氟沙星(LVX),莫西沙星(MXF) ,曲伐沙星(TVA)在类似的AUC / MIC上的作用范围为58到932 h。每个喹诺酮与特定的细菌菌株无关的AUC / MIC与抗菌作用(IE)相关。根据IE-log AUC / MIC关系,预测GRX,MXF和TVA(75至78小时),GAT和GEM(95至95小时,相当于CIP AUC / MIC比为125 h的断点(BP) 103小时)和LVX(115小时)。使用GRX和LVX,预测的BP接近于临床设置中确定的BP(文献中没有其他喹诺酮类药物的临床数据)。为了确定预测的AUC / MIC BP是否可以在临床剂量即治疗性AUC(AUCthers)达到,研究了AUCther / MIC50的比率。这些比例超过了GAT,GEM,GRX,MXF,TVA和LVX(750 mg)的BP,但没有超过CIP和LVX(500 mg)的BP。高于BP的AUC / MIC比可以认为是喹诺酮类药物的治疗潜力。 TVA,MXF和GEM的AUCther / MIC50与BP比率最高(2.5到3.0); GAT和GRX达到中等比率(1.5至1.6); CIP和LVX达到最小比例(0.3到1.2)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号